These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 27236168

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A review of the rationale and clinical utilization of α2-adrenoceptor agonists for the treatment of attention-deficit/hyperactivity and related disorders.
    Sallee F, Connor DF, Newcorn JH.
    J Child Adolesc Psychopharmacol; 2013 Jun; 23(5):308-19. PubMed ID: 23782125
    [Abstract] [Full Text] [Related]

  • 3. The role of alpha2-adrenergic agonists in attention-deficit/hyperactivity disorder.
    Sallee FR.
    Postgrad Med; 2010 Sep; 122(5):78-87. PubMed ID: 20861591
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Long-term outcomes with medications for attention-deficit hyperactivity disorder: current status of knowledge.
    Huang YS, Tsai MH.
    CNS Drugs; 2011 Jul; 25(7):539-54. PubMed ID: 21699268
    [Abstract] [Full Text] [Related]

  • 12. ▼Guanfacine for ADHD in children and adolescents.
    Drug Ther Bull; 2016 May; 54(5):56-60. PubMed ID: 27173784
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Optimizing outcomes in ADHD treatment: from clinical targets to novel delivery systems.
    Mattingly GW, Anderson RH.
    CNS Spectr; 2016 Dec; 21(S1):45-59. PubMed ID: 28044946
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [An update on the pharmacological treatment of attention deficit hyperactivity disorder: lisdexamphetamine and extended-release guanfacine].
    Martin Fernandez-Mayoralas D, Fernandez-Perrone AL, Munoz-Jareno N, Fernandez-Jaen A.
    Rev Neurol; 2017 Mar 13; 64(s02):S1-S8. PubMed ID: 28272733
    [Abstract] [Full Text] [Related]

  • 17. Nonstimulant Treatments for ADHD.
    Newcorn JH, Krone B, Dittmann RW.
    Child Adolesc Psychiatr Clin N Am; 2022 Jul 13; 31(3):417-435. PubMed ID: 35697393
    [Abstract] [Full Text] [Related]

  • 18. Effects of FDA advisories on the pharmacologic treatment of ADHD, 2004-2008.
    Kornfield R, Watson S, Higashi AS, Conti RM, Dusetzina SB, Garfield CF, Dorsey ER, Huskamp HA, Alexander GC.
    Psychiatr Serv; 2013 Apr 01; 64(4):339-46. PubMed ID: 23318985
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.